Transcriptional and spatial profiling of fibroblasts from human lungs highlights CTHRC1+ cells as fibrogenic signaling hubs in fibrosis

By integrating single-cell and spatial transcriptomics of human lung tissue with cultured fibroblast profiling, this study identifies CTHRC1+ fibroblasts as key pro-fibrotic signaling hubs in idiopathic pulmonary fibrosis while revealing that standard in vitro culture conditions significantly distort native fibroblast identity and diversity.

The Gist

The Big Picture: The "Construction Crew" Gone Wild

Imagine your lungs are a bustling city. The fibroblasts are the city's construction crew. In a healthy city, these workers do a great job: they fix small potholes, maintain the roads, and keep the buildings (alveoli) standing tall. They are diverse, with different teams specializing in different jobs (some fix the pipes, some reinforce the walls, some manage traffic).

Idiopathic Pulmonary Fibrosis (IPF) is what happens when this construction crew goes into a permanent, chaotic overdrive. Instead of fixing small issues, they start building massive, useless concrete walls everywhere. This turns the soft, spongy lung tissue into a hard, scarred block, making it impossible to breathe.

This study is like a high-tech investigation that asks two big questions:

1. Who are the ringleaders causing this chaos in the actual lung tissue?
2. Why do our lab experiments fail to catch these ringleaders?

---

Part 1: The "CTHRC1+" Crew – The Master Builders of Scars

The researchers took lung tissue from patients with IPF and healthy older adults and used a super-powerful microscope (single-cell RNA sequencing) to read the "instruction manuals" (genes) of every single cell.

The Discovery:
They found that the lung construction crew isn't just one big group; it's made of six distinct sub-teams.

• The Alveolar Team: The general maintenance crew.
• The Adventitial Team: The ones who work near the blood vessels.
• The Inflammatory Team: The ones who respond to trouble.
• The Smooth Muscle Team: The ones who control the airways.
• The Peribronchial Team: The ones near the air tubes.
• The CTHRC1+ Team: The Villains.

The Analogy:
Think of the CTHRC1+ cells as the "Master Builders" of the disease.

• Where they live: In healthy lungs, they are rare, like a few specialized architects. But in IPF lungs, they multiply wildly and move into the most damaged areas, called fibroblastic foci. These foci are like the "ground zero" of the construction disaster.
• What they do: They are the ones shouting the loudest, ordering up massive amounts of collagen (the concrete) and MMPs (tools that tear down old structures to build new ones). They are the central hubs, sending out signals to other cells to keep the construction going.
• The Result: They turn the lung into a concrete jungle.

The study also found that these Master Builders are connected to the "Inflammatory Team." It's a toxic feedback loop: the inflammation wakes up the Master Builders, and the Master Builders make the inflammation worse.

---

Part 2: The "Lab Trap" – Why Our Experiments Are Lying to Us

Here is the most surprising and critical part of the paper. Scientists have been studying these lung cells in petri dishes (labs) for decades to find cures. But this study shows that the lab environment changes the cells so much that they forget who they are.

The Analogy:
Imagine you take a wild, free-spirited artist (a fibroblast from a human lung) and put them in a tiny, sterile, white room with a strict schedule (a petri dish).

• In the wild (the lung): The artist is part of a complex community, interacting with neighbors, feeling the texture of the ground, and creating unique, specialized art.
• In the lab: After a few weeks, the artist stops being unique. They all start looking the same, wearing the same uniform, and painting the same generic picture. They lose their "specialty."

What the Study Found:

1. The Disappearance: When scientists took lung tissue and grew the cells in a dish, the CTHRC1+ Master Builders completely vanished. They couldn't be found in the lab cultures.
2. The Imposter: Instead, the cells that grew in the lab were mostly "Alveolar" cells that had been forced into a generic, stressed state. They started acting like the Master Builders (making lots of collagen), but they weren't the real Master Builders.
3. The Drift: As the cells were passed from one dish to another (passage 1 to passage 6), they drifted further away from their natural state. They started acting like they were in a panic (inflammation) or getting old (senescence), rather than acting like healthy lung cells.

The "CTHRC1" Confusion:
The study found that in the lab, almost every type of cell started making the "CTHRC1" protein because the plastic dish was stressing them out. It's like if you put a whole orchestra in a tiny room, and everyone starts screaming the same note because they are uncomfortable. You can no longer tell who the conductor was supposed to be.

---

Part 3: The Takeaway – What This Means for You

1. We missed the real target.
For years, drug companies have been testing medicines on cells grown in petri dishes. But if the "Master Builders" (CTHRC1+ cells) disappear in the dish, then the drugs tested on the "imposters" might not work on the real disease in the human body. It's like trying to fix a leaky roof by testing your patch on a piece of cardboard instead of the actual roof.

2. We need better models.
To find a cure, we need to stop relying solely on cells in plastic dishes. We need to study the cells inside the tissue (using the new spatial mapping techniques used in this paper) or create lab environments that mimic the complex, 3D world of the lung.

3. The Map is Complete.
This paper provides the first high-resolution "Google Map" of the lung construction crew. It tells us exactly where the bad guys (CTHRC1+ cells) live, what tools they use, and who they talk to. Now, scientists can design drugs that specifically target these Master Builders without hurting the good workers.

Summary in One Sentence

This study reveals that the true "villains" of lung scarring are a specific group of cells called CTHRC1+, which disappear when we try to study them in a lab, explaining why many current treatments fail and urging us to look at the cells in their natural, complex environment to find a cure.

Technical Summary

1. Problem Statement

Idiopathic Pulmonary Fibrosis (IPF) is a fatal lung disease driven by aberrant extracellular matrix (ECM) remodeling and fibroblast activation. While fibroblasts are central to IPF pathogenesis, their study is hindered by two major challenges:

• Inaccessibility: Fibroblasts are embedded deep within the lung ECM, making isolation difficult.
• Culture-Induced Artifacts: Standard in vitro culture on rigid 2D plastic surfaces causes significant phenotypic drift. Fibroblasts lose native transcriptional identities, gain stress/proliferative markers, and fail to recapitulate the heterogeneity observed in vivo.
• Knowledge Gap: There is a lack of high-resolution maps comparing native fibroblast subtypes in IPF tissue versus their in vitro counterparts, specifically regarding how culture conditions alter the identity of disease-relevant subpopulations (e.g., the pro-fibrotic CTHRC1+ cells).

2. Methodology

The study employed an integrative multi-omics approach combining in vivo tissue profiling with in vitro culture analysis:

• Cohorts: Lung tissues from IPF patients (upper and lower lobes) and age-matched healthy donors (>55 years).
• Isolation Protocols: Primary fibroblasts were isolated using three distinct methods to assess protocol bias:
  1. Whole Lung Cell Suspension (WLCS): Enzymatic digestion followed by plastic adherence.
  2. Negative Fraction Enrichment: Magnetic bead depletion of immune, endothelial, and epithelial cells.
  3. Outgrowth: Fibroblasts migrating out of tissue explants.
• Sequencing Strategy:
  • scRNA-seq (Tissue): Performed on FFPE sections to capture the native cellular landscape.
  • Spatial Transcriptomics (Xenium In Situ): Used to map fibroblast subtypes and ECM gene expression within specific histological structures (e.g., fibroblastic foci).
  • scRNA-seq (Culture): Fibroblasts were profiled at Passage 1 (P1) and Passage 6 (P6) to track transcriptional drift over time.
• Computational Analysis:
  • Clustering & Annotation: Leiden algorithm and UMAP for identifying mesenchymal subtypes.
  • Trajectory Inference: PAGA and Monocle3 for pseudotime analysis; Waddington Optimal Transport (WOT) to model state transitions between tissue and culture.
  • Cell-Cell Communication: CellChat for ligand-receptor interaction analysis.
  • Pathway Analysis: Gene Ontology (GO) enrichment and transcription factor (TF) activity inference (CollecTRI).

3. Key Contributions & Results

A. Identification of Six Distinct Fibroblast Subtypes in Native Tissue

Single-cell analysis of lung tissue revealed six transcriptionally distinct mesenchymal subtypes:

1. Alveolar: Marked by NPNT, TCF21, INMT.
2. Adventitial: Marked by MFAP5, SCARA5, SFRP2.
3. Inflammatory: Marked by chemokines (CXCL2, CXCL8, CCL2).
4. Peribronchial: Marked by WIF1, FGF18, ASPN.
5. Smooth Muscle Cells (SMC): Marked by contractile genes (ACTA2, MYH11).
6. CTHRC1+: A novel, highly activated pro-fibrotic subtype defined by CTHRC1, TGFB1, POSTN, and COL10A1.

B. CTHRC1+ Fibroblasts as the Primary Fibrogenic Hubs

• Transcriptional Activity: CTHRC1+ cells exhibited the highest upregulation of ECM biosynthesis genes (collagens, MMPs) and matricellular proteins.
• Spatial Localization: Spatial transcriptomics confirmed that CTHRC1+ cells are preferentially enriched within fibroblastic foci (the active lesions of IPF), co-localizing with high collagen and MMP expression.
• Signaling Hubs: CellChat analysis revealed that in IPF, CTHRC1+ cells become the dominant senders of pro-fibrotic signals (collagen, fibronectin, periostin), while inflammatory fibroblasts act as primary receivers. This signaling axis is most pronounced in the lower lobes (severe disease).
• Trajectory: Pseudotime analysis suggests a directional continuum from alveolar and inflammatory fibroblasts toward the CTHRC1+ state, driven by TFs like RUNX2, CREB3L1, and SCX.

C. The "Culture Drift" Phenomenon

Comparing tissue-derived data with cultured fibroblasts (P1 vs. P6) revealed severe limitations of standard in vitro models:

• Loss of Identity: Native subtype markers (e.g., CTHRC1, WIF1, ASPN) were largely lost or undetectable in culture.
• Acquisition of Stress Programs: Cultured cells acquired inflammatory (CXCL8, CXCL12), proliferative (MKI67), and senescence (CDKN1A, GDF15) signatures regardless of disease origin.
• CTHRC1+ Disappearance: The distinct CTHRC1+ cluster found in tissue did not form in culture. Instead, CTHRC1 expression was broadly upregulated across all cultured subtypes, erasing the specific identity of the pro-fibrotic hub.
• Drift Quantification: Using WOT, the study showed that:
  • SMCs were most resistant to drift (retained identity).
  • Alveolar fibroblasts showed intermediate drift.
  • CTHRC1+ and Inflammatory fibroblasts were the most plastic, converging toward generic "Alveolar 1/2" or "Proliferating" states in culture.

D. Protocol-Specific Variations

While all protocols suffered from drift, the Outgrowth method showed slightly better retention of certain markers but still failed to preserve the CTHRC1+ distinctiveness. The WLCS and Negative Fraction protocols captured broader heterogeneity initially but showed greater inter-passage variability in IPF samples.

4. Significance and Implications

• Redefining the Pro-Fibrotic Cell: The study identifies CTHRC1+ fibroblasts as the critical, spatially organized effector cells in IPF fibroblastic foci, challenging the previous focus solely on myofibroblasts or generic "activated" fibroblasts.
• Critique of In Vitro Models: The findings provide strong evidence that standard 2D culture systems fail to model the specific CTHRC1+ pro-fibrotic state. The culture-induced upregulation of CTHRC1 across all subtypes masks the specific biology of the disease-relevant population.
• Therapeutic Implications:
  • Therapies targeting generic "activated" fibroblasts in culture may miss the specific mechanisms driving the CTHRC1+ hub in vivo.
  • Future drug screening must account for the loss of subtype fidelity in culture.
  • New in vitro models (e.g., 3D cultures, mechanosensitive substrates) are needed to preserve the CTHRC1+ identity.
• Mechanistic Insight: The study elucidates a disease-stage-dependent rewiring of intercellular communication, where the loss of homeostatic signaling (laminin/Notch) and the dominance of collagen-integrin signaling by CTHRC1+ cells drive fibrosis progression.

In summary, this paper provides a high-resolution atlas of lung fibroblast heterogeneity, establishes CTHRC1+ cells as the central drivers of IPF pathology, and rigorously demonstrates that standard culture conditions fundamentally alter fibroblast identity, necessitating a re-evaluation of how fibroblast-targeted therapies are developed and tested.